Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04765059
Title A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COMPEL)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-squamous non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium

Cisplatin + Osimertinib + Pemetrexed Disodium

Carboplatin + Osimertinib + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA | ITA | ESP | DEU | AUT


No variant requirements are available.